The abstract is read at the publisher; the summary is JClub's.
Improving valsartan permeability via its ethyl ester prodrug enables effective inhibition of SUGCT in GA-1 cells, and meclofenamic acid is identified as a new cell-active SUGCT inhibitor.
- Why it matters: GA-1 has no pharmacological treatment, and toxic lysine-pathway metabolite accumulation remains a major unmet need; SUGCT is a promising therapeutic target based on prior mouse work.
- What they did: The team ran additional in vitro high-throughput screening and built an improved cell-based assay for detecting SUGCT inhibition, then tested prodrug-enhanced valsartan and screened for new inhibitors.
- The result: In GA-1 cells, ethyl ester valsartan effectively inhibits SUGCT, and meclofenamic acid shows cellular SUGCT inhibition, strengthening the case for targeting this enzyme in GA-1.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.